Concepedia

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, F. Matzkies, Mark C. Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartók, Angelika Jahreis,

Annals of the Rheumatic Diseases · 2021 · 78 citations · 27 references

Open access

References

27

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

Daniel Aletaha, Tuhina Neogi, Alan J. Silman et al. · Arthritis & Rheumatism · 2010 · 9.3K citations · Full text

SIMPLE METHOD TO CALCULATE THE CONFIDENCE INTERVAL OF A STANDARDIZED MORTALITY RATIO (SMR)

K. Ulm · American Journal of Epidemiology · 1990 · 556 citations

Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study

Alexis Ogdie, Yiding Yu, Kevin Haynes et al. · Annals of the Rheumatic Diseases · 2014 · 473 citations · Full text

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Stanley Cohen, Yoshiya Tanaka, Xavier Mariette et al. · Annals of the Rheumatic Diseases · 2017 · 381 citations · Full text

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Paqui G. Través, Bernard P. Murray, Federico Campigotto et al. · Annals of the Rheumatic Diseases · 2021 · 307 citations · Full text